CliffBio
small molecule

EVZIO (AUTOINJECTOR)

NALOXONE HYDROCHLORIDE

Loss of exclusivityMarch 2035latest FDA-listed patent expiry
CompanyKaleo →View the full company profile on CliffBio

Drug detail

Brand nameEVZIO (AUTOINJECTOR)
Active ingredientNALOXONE HYDROCHLORIDE
Strength2MG/0.4ML (2MG/0.4ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
10220158March 2035product
9517307July 2034product
8627816February 2032product
10143792May 2031use U-2476
9022022February 2031product
10322239February 2031use U-1907
8939943February 2031product
9474869February 2031product
8021344November 2029product
8226610April 2029product
8231573November 2028product
7749194October 2028product
7947017March 2028product
9724471May 2027product
8206360February 2027product
9238108February 2027product
11590286December 2026product
10960155June 2026product
7731686June 2026product
8926594March 2026product
9278182February 2026product

More from Kaleo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EVZIO (AUTOINJECTOR) patent cliff — loss of exclusivity March 2035 | CliffBio